Comparative Pharmacology
Head-to-head clinical analysis: DYNACIRC CR versus SULAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIRC CR versus SULAR.
DYNACIRC CR vs SULAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
10-20 mg orally once daily; maximum 60 mg/day.
None Documented
None Documented
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker